St. Jude FlexAbility Ablation Trial For Ventricular Tachycardia
This article was originally published in The Gray Sheet
Executive Summary
The company will be recruiting around 1,450 patients at 50 U.S. sites during the next four to five years to prove its ablation therapy is a valuable addition to ICDs or CRT-Ds to reduce recurrent ventricular tachycardia.